Skip to Main Content
Back to News

TANDEM DIABETES CARE Earnings Results: $TNDM Reports Quarterly Earnings

None

TANDEM DIABETES CARE ($TNDM) posted quarterly earnings results on Wednesday, August 6th. The company reported earnings of -$0.48 per share, missing estimates of -$0.41 by $0.07. The company also reported revenue of $240,680,000, missing estimates of $243,345,888 by $-2,665,888.

You can see Quiver Quantitative's $TNDM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

TANDEM DIABETES CARE Insider Trading Activity

TANDEM DIABETES CARE insiders have traded $TNDM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $TNDM stock by insiders over the last 6 months:

  • JEAN-CLAUDE KYRILLOS (EVP & Chief Operating Officer) purchased 10,538 shares for an estimated $190,966

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

TANDEM DIABETES CARE Hedge Fund Activity

We have seen 134 institutional investors add shares of TANDEM DIABETES CARE stock to their portfolio, and 178 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

TANDEM DIABETES CARE Congressional Stock Trading

Members of Congress have traded $TNDM stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $TNDM stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

TANDEM DIABETES CARE Analyst Ratings

Wall Street analysts have issued reports on $TNDM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

  • Citigroup issued a "Sell" rating on 07/09/2025
  • Canaccord Genuity issued a "Buy" rating on 05/01/2025
  • Stifel issued a "Buy" rating on 05/01/2025
  • Piper Sandler issued a "Overweight" rating on 05/01/2025
  • Barclays issued a "Overweight" rating on 02/28/2025
  • RBC Capital issued a "Outperform" rating on 02/27/2025

To track analyst ratings and price targets for TANDEM DIABETES CARE, check out Quiver Quantitative's $TNDM forecast page.

TANDEM DIABETES CARE Price Targets

Multiple analysts have issued price targets for $TNDM recently. We have seen 12 analysts offer price targets for $TNDM in the last 6 months, with a median target of $24.0.

Here are some recent targets:

  • Joanne Wuensch from Citigroup set a target price of $14.0 on 07/09/2025
  • Richard Newitter from Truist Securities set a target price of $24.0 on 06/16/2025
  • William Plovanic from Canaccord Genuity set a target price of $59.0 on 05/01/2025
  • Mathew Blackman from Stifel set a target price of $31.0 on 05/01/2025
  • Larry Biegelsen from Wells Fargo set a target price of $20.0 on 05/01/2025
  • Matt O'Brien from Piper Sandler set a target price of $30.0 on 05/01/2025
  • Jeff Johnson from Baird set a target price of $24.0 on 05/01/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles